106 Results for "

HUVEC

" in MedChemExpress (MCE) Product Catalog:
Products (106)

106 Results for "HUVEC" in MCE Product Catalog:

Cat. No.: HY-161863
Tubulin polymerization-IN-67 (Compound 5h) is an inhibitor for tubulin polymerization on colchicine binding site with an IC50 of 2.92 μM. Tubulin polymerization-IN-67 inhibits the proliferation of cancer cells HT29, A549, U2OS, MG-63 and HeLa with IC50s of 0.12-4.13 μM. Tubulin polymerization-IN-67 arrests the cell cycle at G2/M phase, induces apoptosis in cell U2OS, inhibits the cell migration of A549. Tubulin polymerization-IN-67 reduces the mitochondrial membrane potential (MMP) and increase intracellular ROS, inhibits the angiogenesis in HUVECs. Tubulin polymerization-IN-67 exhibits antitumor efficacy in mice
loading...
    loading...
Cat. No.: HY-121605S
RL71-d6 is a deuterium labeled RL71 (HY-121605). RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks .
loading...
    loading...
Cat. No.: HY-155721
CAS No.: 1178895-15-2
Synonyms: 22-4′-Pyridinecarbonyl jorunnamycin A
Target:  

Akt mTOR

Research Areas:  

Cancer

22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-164530
CAS No.: 1970149-05-3
Target:  

Src VEGFR Raf p38 MAPK

Research Areas:  

Cancer

SKLB646 is an orally active multi-target kinase inhibitor. SKLB646 shows significant inhibitory effects on SRC and VEGFR2 with IC50 values ??of 0.002 μmol/L and 0.012 μmol/L, respectively. SKLB646 also shows significant inhibitory effects on B-Raf and C-Raf with IC50 values ??of 0.022 μmol/L and 0.019 μmol/L, respectively. SKLB646 inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinase. In addition, SKLB646 can inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC) to inhibit tumor-induced angiopoietic formation. SKLB646 shows significant anti-proliferative and anti-survival activities against triple-negative breast cancer (TNBC) cell lines .
loading...
    loading...
Cat. No.: HY-117991
CAS No.: 1804982-31-7
Target:  

VEGFR

Research Areas:  

Cancer

DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
loading...
    loading...
Cat. No.: HY-168127
Target:  

VEGFR

Research Areas:  

Cancer

VEGFR-2-IN-57 (compound 6n) exhibited significant cytotoxicity in HUVEC cells (IC50 = 28.77 nM).
loading...
    loading...
Cat. No.: HY-118273
CAS No.: 1185036-77-4
Target:  

Integrin

Research Areas:  

Inflammation/Immunology Cancer

IPS-05002 is an α5β1 antagonist. IPS-05002 can inhibit VEGF-stimulated human umbilical vein endothelial cell (HUVEC) proliferation, adhesion, and migration, and also suppresses tubular network formation. IPS-05002 can upregulate IKB-β, XRCC4, and downregulate Cdc6 in VEGF-induced HUVECs. IPS-05002 can be used for the study of tumor angiogenesis .
loading...
    loading...
Cat. No.: HY-W702106
CAS No.: 1818-12-8
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

2-Methyl estradiol, an endogenous metabolite of Estradiol (HY-B0141), inhibits cell proliferation and angiogenesis, with IC50 values of 3 and 2.39 μM for HUVEC and MCF-7 human breast cancer cell proliferation, respectively .
loading...
    loading...
Cat. No.: HY-K6026

MCE In Vitro Angiogenesis Basement Membrane Matrix (Ready-to-Use) is formulated in high-glucose DMEM and contains 50 μg/mL gentamicin. With an optimized formulation and working concentration, it requires no additional dilution or preparation and can be directly used for in vitro tube formation assays with HUVECs and other endothelial cells, supporting the establishment of in vitro angiogenesis models and related research.

loading...
    loading...
Cat. No.: HY-W009749CR
CAS No.: 61125-50-6
L-Cystathionine dihydrochloride (Standard) is the analytical standard of L-Cystathionine dihydrochloride (HY-W009749C). This product is intended for research and analytical applications. L-Cystathionine dihydrochloride is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine dihydrochloride protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine dihydrochloride plays an important role in cardiovascular protection.
loading...
    loading...
Cat. No.: HY-K3003

DMEM (Dulbecco's Modified Eagle Medium) is a widely used basal medium for supporting the growth of many different mammalian cells. Cell lines successfully cultured in DMEM include Hela, 293, Cos-7, and PC-12, as well as primary fibroblasts, neurons, glial cells, HUVECs, and smooth muscle cells, etc. The 500 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

loading...
    loading...
Cat. No.: HY-N19782
CAS No.: 851278-60-9
Striatisporolide A is an antibacterial agent. Striatisporolide A exhibits antibacterial activity against Escherichia coli in vitro. Striatisporolide A damages the cell wall and cell membrane of Escherichia coli, and induces changes in protein levels and morphology. Striatisporolide A reduces the level of apoptosis (apoptosis) in HUVECs, inhibits excessive production of ROS, and possesses pro-proliferative and mild cytoprotective effects. Striatisporolide A can be used in studies related to bacterial infections and degenerative diseases .
loading...
    loading...
Cat. No.: HY-183768
Target:  

PROTACs FAK

Research Areas:  

Cancer

PROTAC FAK degrader 5 is a potent PROTAC degrader targeting FAK, with a DC50 of 11.65 nM. PROTAC FAK degrader 5 induces FAK protein degradation, selectively inhibits colony formation of human colorectal cancer HCT116 cells, and blocks the proliferation of human umbilical vein endothelial HUVEC cells, exhibiting anti-angiogenic activity. PROTAC FAK degrader 5 can be used in the research of colorectal cancer and angiogenesis .
loading...
    loading...
Cat. No.: HY-P991896
Synonyms: AT14-012
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
loading...
    loading...
Cat. No.: HY-N17779
CAS No.: 173658-86-1
3-O-Caffeoyl-5-O-feruloylquinic acid is a quinic acid-based phenolic compound that can be isolated from Eryngium bourgatii. 3-O-Caffeoyl-5-O-feruloylquinic acid regulates free radical scavenging and inflammatory pathways, exerting antioxidant activity through electron transfer and hydrogen atom transfer mechanisms. It also inhibits TNF-α-induced reactive oxygen species (ROS) production and the production of monocyte chemoattractant protein-1 (MCP-1) and its transcripts in human umbilical vein endothelial cells (HUVECs).
loading...
    loading...
Cat. No.: HY-126010R
CAS No.: 2253744-54-4
Research Areas:  

Cardiovascular Disease

Dooku1 (Standard) is the analytical standard of Dooku1 (HY-126010). This product is intended for research and analytical applications. Dooku1 is a reversibly Yoda1 antagonist with IC50 value of 1.3 μM and 1.5 μM for 2 μM Yoda1-induced Ca 2+ entry HEK 293 cells and HUVECs, respectively. Dooku1 can disrupt Yoda1-induced Piezo1 channel activity and inhibit Yoda1-induced relaxation of aorta. Dooku1 can be used for vascular physiology and disease research .
loading...
    loading...
Cat. No.: HY-180159
Research Areas:  

Cancer

Tubulin-IN-63 is a potent tubulin polymerization inhibitor targeting the colchicine-binding site, with an IC50 of 6.03 µM. Tubulin-IN-63 disrupts microtubule dynamics, induces G2/M arrest and apoptosis, thereby suppressing cancer cell proliferation. Tubulin-IN-63 disrupts capillary network formation in human umbilical vein endothelial cells (HUVECs) and exhibits in vivo antitumor efficacy in a B16-F10 mouse model. Tubulin-IN-63 can be used for the research of cancers, such as melanoma, lung cancer, and liver cancer .
loading...
    loading...
Cat. No.: HY-18198
CAS No.: 1346265-80-2
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

BRN-103 is a nicotinamide derivative and an inhibitor of the VEGF/VEGFR2 angiogenesis signaling pathway. BRN-103 concentration-dependently inhibits VEGF-induced migration, proliferation and capillary-like tube formation of HUVECs, and suppresses microvascular sprouting of ex vivo aortic rings. BRN-103 inhibits VEGF-induced phosphorylation of VEGFR2 Tyr1175, as well as the downstream phosphorylation of AKT Ser473 and eNOS Ser1172, while exerting a weak inhibitory effect on ERK phosphorylation. BRN-103 can be used in studies related to VEGF/VEGFR2 signaling and angiogenesis .
loading...
    loading...
Cat. No.: HY-117733
CAS No.: 176050-48-9
Zerumin A is an anti-angiogenic agent that acts on multiple molecular targets related to angiogenesis (including kdr/VEGFR2, angpt1, angpt2, tie1, and tie2). Zerumin A specifically inhibits the proliferation and migration of human umbilical vein endothelial cells (HUVECs) by regulating the VEGF-VEGFR and ANGPT-TIE signaling pathways, and dose-dependently inhibits angiogenesis (10-20 μM significantly inhibits zebrafish embryo angiogenesis). Zerumin A can be used in the research of cancer and angiogenesis-related inflammatory diseases. Zerumin A can be naturally extracted from the 95% ethanol extract of the fruits, seeds, and pericarp of Alpinia caerulea (R.Br.) Bentham (a plant of the Alpinia genus in the Zingiberaceae family) .
loading...
    loading...
Cat. No.: HY-184741
Target:  

GSK-3 VEGFR Akt MEK ERK

Research Areas:  

Cancer

GSK-3β/VEGFR2-IN-1 is an orally active dual inhibitor of GSK-3β (IC50 = 325 nM) and VEGFR2 (IC50 = 78 nM). GSK-3β/VEGFR2-IN-1 suppresses the phosphorylation of VEGFR2, AKT, MEK and ERK, inhibits human tongue squamous cell carcinoma cells migration and suppresses formation of HUVECs, exhibits low toxicity towards other cancer cells and normal cells, demonstrates significant antitumor efficacy in a CAL27 xenograft mouse model. GSK-3β/VEGFR2-IN-1 can be used for the study of tongue squamous cell carcinoma .
loading...
    loading...